Key Moments
- ResMed stock fell 5.5% in pre-market trading after reporting mixed Q4 FY2026 results with an earnings beat but a slight revenue miss.
- The company issued its first-ever FY2027 outlook, guiding for 5–7% core revenue growth versus 8% constant-currency growth in FY2026, including a $75 million headwind from an Astral ventilator field safety action.
- Planned divestiture of MatrixCare and the $340 million Noctrix Health acquisition are expected to dilute EPS, while several analysts cut their price targets following the update.
Market Reaction to Quarterly Results
ResMed stock was down 5.5% in pre-open trading after the sleep and respiratory care device manufacturer released Q4 FY2026 results on Thursday evening that fell short of investor expectations for a clean beat. The company posted non-GAAP EPS of $2.95, an increase of 16% year-over-year and ahead of the roughly $2.89 consensus estimate. However, revenue came in at $1.46 billion, narrowly below the approximately $1.47 billion that Wall Street had anticipated.
First Full-Year Guidance Disappoints
The more consequential development for the stock was ResMed’s first-ever full-year outlook for FY2027. Management projected core revenue growth of only 5–7%, below the 8% constant-currency growth the company delivered in FY2026. The guidance incorporates a $75 million revenue headwind tied to a field safety action affecting the Astral ventilator product line, which is weighing on the growth trajectory.
Strategic Moves and EPS Dilution
ResMed’s near-term earnings profile is also being affected by portfolio changes. The company is preparing to divest its MatrixCare software business, and it recently completed a $340 million acquisition of Noctrix Health. Both actions are expected to dilute EPS in the coming year, adding another layer of pressure to the outlook.
Analyst Response and Broader Market Context
Following the earnings release and guidance, multiple analysts, including RBC Capital and Wells Fargo, reduced their price targets on ResMed shares. The reaction took place against a relatively calm broader market backdrop, with the S&P 500 described as essentially flat and the Nasdaq modestly higher. As a result, the pre-market move in ResMed appeared driven by company-specific developments rather than broader macro factors.
Insider Transaction and Trading Range
Sentiment around the stock also absorbed news of an insider sale ahead of the results. A director sold $1.8 million worth of shares at $225 per share on August 5 under a pre-arranged trading plan. While such scheduled sales are generally not viewed as a directional indicator, the transaction added some headline noise before the earnings announcement.
In combination, the revenue miss, slower projected FY2027 core revenue growth, the Astral-related revenue impact, and analyst target cuts created a wave of selling interest. ResMed’s share price moved significantly below the prior session close of $223.24, leaving the stock closer to the lower end of its 52-week range of $180.26–$293.81.
Key Figures at a Glance
| Metric | Value |
|---|---|
| Q4 FY2026 non-GAAP EPS | $2.95 |
| Consensus EPS estimate | ~$2.89 |
| Q4 FY2026 revenue | $1.46 billion |
| Consensus revenue estimate | ~$1.47 billion |
| FY2027 core revenue growth guidance | 5–7% |
| FY2026 constant-currency revenue growth | 8% |
| Astral ventilator-related revenue headwind | $75 million |
| Noctrix Health acquisition value | $340 million |
| Director share sale | $1.8 million at $225 per share |
| Previous session closing price | $223.24 |
| 52-week trading range | $180.26–$293.81 |
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
